![](/img/cover-not-exists.png)
Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
Llacer Perez, C., Romero Laorden, N., Lozano Mejorada, R., Piulats, J.M., Puente, J., Lorente Estelles, D., Medina, A., Cattrini, C., Vitrone, F.M., Almagro, E., Borrega GarcÃa, P., Lainez, N., RiverVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.887
Date:
September, 2020
File:
PDF, 109 KB
2020